Arzneimittelforschung 2008; 58(7): 317-322
DOI: 10.1055/s-0031-1296513
CNS-active Drugs · Hypnotics · Psychotropics · Sedatives
Editio Cantor Verlag Aulendorf (Germany)

Effect of Perindopril on Vasoreactivity in Patients with Hypertensive Chronic Cerebrovascular Disease

A comparative analysis of different brain structures
Nobuhiro Inoue
Department of Neurosurgery, Kumamoto Neurosurgical Hospital, Kumamoto, Japan
Mikio Harada
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)


Background and purpose:

The angiotensin-converting enzyme inhibitor perindopril (CAS 107133-36-8) helps to prevent stroke recurrence by improving cerebral vasomotor reactivity (CVR). Perindopril-induced vasoreactivity changes in different brain structures of patients with chronic cerebrovascular disease were compared.


The study population consisted of 6 hypertensive patients (mean age 65.5 ± 9.9) who had experienced a cerebrovascular event; three each had minor ischemic episodes and hemorrhage. The administration of 4 mg/day perindopril was started one month after stroke onset; the follow-up lasted more than one year. Their cerebral blood flow (CBF), assessed at the start of perindopril administration and again 3 months later, was examined both at rest and after the administration of 15 mg/kg acetazolamide and the CVR was calculated. Regions of interest were cortical and subcortical areas on the CT scans.


In the course of this study, none of the patients suffered stroke recurrence. The 3-month administration of perindopril lowered their systemic blood pressure without decreasing CBF and significantly increased cerebral vasoreactivity in the lesioned (p = 0.04355) and contralateral (p = 0.04090) cortical areas without producing significant changes in CVR in the subcortical gray matter (striatum and thalamus).


The CVR in cortical structures recovered sooner than that in subcortical gray matter. Although the number of stroke patients included in this study was small, it is concluded that this phenomenon may be attributable to the earlier vasoreactivity increase in the cortical vessels than the subcortical perforators.

  • References

  • 1 PROGRESS Collaborative Group. Randomised trial of a perindopril – based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001; 358: 1033-1044
  • 2 Chapman N, Huxley R, Anderson DC, Bousser MG, Chalmers J, Colman S et al. Effects of perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS Trial Stroke. 2004; 35: 116-121
  • 3 Arima H, Tzourio C, Butcher K, Anderson C, Bousser MG, Lees KR et al. for the PROGRESS Collaborative Group. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS Trial. Stroke. 2006; 37: 1497-1502
  • 4 Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke. 1997; 28: 580-583
  • 5 Walters MR, Bolster A, Dyker AG, Lees KR. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke. 2001; 32: 473-478
  • 6 Hatazawa J, Shimosegawa E, Osaki Y, Ibaraki M, Oku N, Hasegawa S et al. Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke. 2004; 35: 2117-2122
  • 7 Walters M, Muir S, Shah I, Lees K. Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction. Stroke. 2004; 35: 1899-1902
  • 8 Shinohara Y. Mechanism of chemical control of cerebral vasomotor activity. Neurology. 1973; 23: 186-195
  • 9 Rogg J, Rutigliano M, Yonas H, Johnson D, Pentheny S, Latchaw R. The acetazolamide challenge: imaging techniques designed to evaluate cerebral blood flow reserve. AJNR. 1989; 10: 803-810
  • 10 Herold S, Brown MM, Frackowiak RS, Mansfield AO, Thomas DJ, Marshall J. Assessment of cerebral hemodynamic reserve: correlation between PET parameters and CO2 reactivity measured by the intravenous 133Xe injecton technique. J Neurol Neurosurg Psychiatry. 1988; 51: 1045-1050
  • 11 Levine RL, Dobkin JA, Rozental JM, Satter MR, Nickles RJ. Blood flow reactivity to hypercapnia in strictly unilateral carotid disease: preliminary results. J Neurol Neurosurg Psychiatry. 1991; 54: 204-209
  • 12 Yonas H, Darby JM, Marks EC, Durham SR, Maxwell C. CBF measured by Xe-CT: approach to analysis and normal values. J Cereb Blood Flow Metab. 1991; 11: 716-725
  • 13 Dean BL, Hodak JA, Drayer BP, Lee C, Grahm TW, Conrad GR. Acetazolamide and stable xenon-enhanced computed tomography: benefits and adverse reactions. In: Cerebral blood flow measurement with stable xenon-enhanced computed tomography. Howard Y. editor New York: Raven Press; 1992. p -156–161
  • 14 Kety SS. The theory and applications of the exchange of inert gas at the lungs and tissue. Pharmacol Rev. 1951; 3: 1-41
  • 15 Gotoh F, Shinohara Y. Role of carbonic anhydrase in chemical cibtrik and autoregulation of cerebral circulation. Int J Neurol. 1977; 11: 219-227
  • 16 Durham SR, Smith HA, Rutigliano MJ. Assesment of cerebral vasoactivity and stroke risk using Xe/CT acetazolamide challenge. Stroke. 1991; 22: 138-
  • 17 Yonas H, Smith HA, Durham SR, Pentheny SL, Johnson DW. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg. 1993; 79: 483-489
  • 18 Segawa H. Normative values. In: Quantitative cerebral blood flow measurements using stable xenon/CT: clinical applications. Tomonaga M, Tanana A, Yonas H. ediors 1995: 61-66 futura Publishing Co., Inc; Armonk NY:
  • 19 Sase S, Honda M, Machida K, Seiki Y. Comparison of cerebral blood flow between perfusion computed tomography and xenon-enhanced computed tomography for normal subjects Territorial analysis. J Comput Assist Tomogr. 2005; 29: 270-277
  • 20 Campbell DJ. Angiotensin-converting enzyme (ACE) inhibitors and kinin metabolism; evidence that ACE inhibitors may inhibit a kinase other than ACE. Clin Exp Pharmacol Physiol. 1995; 22: 903-911
  • 21 Wiemer G, Scholkens A, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-dereived bradykinin. Hypertension. 1991; 18: 558-563
  • 22 Thybo NK, Korsgaard N, Eriksen S, Christensen KL, Mul-bany MJ. Dose-dependent effects of perindopril on blood pressure and small artery structure. Hypertension. 1994; 23: 659-666
  • 23 Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulbany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995; 25: 474-481
  • 24 Toda N, Miyazaki M. Regional and species difference in the resonse of isolated arteries to angiotensin II. Jpn J Pharmacol. 1978; 28: 495-497
  • 25 Chollet F, DiPiero V, Wide RJ, Brooks DJ, Dolan RJ, Frackowiak RS. The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol. 1991; 29: 63-71
  • 26 Willer C, Chollet F, Friston KJ, Wise RJ, Frackowiak RS. Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann Neurol. 1992; 31: 463-472
  • 27 Willer C, Ramsay SC, Wise RJ, Friston KJ, Frackowiak RS. Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. Ann Neurol. 1993; 33: 181-189
  • 28 Ito U, Kuroiwa T, Nagasao J, Kawakami E, Oyanagi K. Temporal profiles of axon terminals, synapses and spines in the ischemic penumbra of the cerebral cortex. Ultrastructure of neuronal remodeling. Stroke. 2006; 37: 2134-2139
  • 29 Frost SB, Barbay S, Friel KM, Plautz EJ, Nudo RJ. Reorganization of remote cortical regions after ischemic brain injury: A potential substrate for stroke recovery. J Neurophysiol. 2003; 89: 3205-3214
  • 30 Alexander GE, Delong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986; 9: 357-381